Application of laser assisted anti-infection therapy for the gum disease around dental implants

The effect of photodynamic therapy with indocyanine green photosensitizer on nonsurgical management of peri-implant diseases and its cytokine profile

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201609281248N3

Enrollment

Registered

2016-10-15

Start date

2016-10-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implant disease. Presence of tooth-root and mandibular implants, Gingivitis and periodontal diseases

Interventions

Intervention 1: The affected sites will be debrided mechanically using ultrasonic devices under local anesthesia. Consequently, a photosensitizer agent ( Indocyanine green) will be inserted into peri-

Treatment - Other

Treatment - Drugs

The affected sites will be debrided mechanically using ultrasonic devices under local anesthesia. The patient will be instructed to wash out his/her mouth and avoid to intake any food/beverages for 2

The affected sites will be debrided mechanically using ultrasonic devices under local anesthesia. Consequently, a photosensitizer agent ( Indocyanine green) will be inserted into peri-implant pockets

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: • Age=18 yr. • Persistence of at least ONE implant with at least ONE year • Persistence of Peri- implant disease Exclusion Criteria: • Using antibiotic from 3 months prior to study • Using NSAIDS and/or corticosteroids on resent 3 mounts, • Presence of any history of any treatment for Peri- implant disease during last 3 mounts • Being a current and/or former smokers , drug or alcohol abuser • Using Bisphosphonates, Cyclosporine, Coumadin, Warfarin and Heparin • Pregnancy and lactation • Presence of an active periodontal disease after therapy • Presence of poorly controlled diabetes and other debilitating diseases • Refraining of consent signature

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bleeding on Probing. Timepoint: 2 weeks, 2 mounths. Method of measurement: Clinical Examination.	—

Secondary

Measure	Time frame
Interleukin 1. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: Labratoary exam.;Probing Depth. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: clinical examination.;Clinical attachment level. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: clinical examination.;Pain on probing. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: clinical examination.;Interleukin 6. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: Labratoary exam.;TNF alpha. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: Labratoary exam.	—

Measure

Time frame

Interleukin 1. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: Labratoary exam.;Probing Depth. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: clinical examination.;Clinical attachment level. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: clinical examination.;Pain on probing. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: clinical examination.;Interleukin 6. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: Labratoary exam.;TNF alpha. Timepoint: baseline, 2 weeks, 2 months. Method of measurement: Labratoary exam.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Reza Pourabbas

Tabriz University of Medical Sciences

rpourabbas@yahoo.com+98 41 3328 1190

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026